As shown in the DAPA-HF (McMurray et al., 2019) and EMPEROR-reduced trials (Packer et al., 2020), SGLT2 inhibitors notably reduce the risk of worsening heart failure (HF) or death from cardiovascular causes in patients with HF and a reduced ejection fraction (HFrEF). The gene discussed is SLC5A2; the disease is heart failure.